Two Decades of PARP Inhibitor Synthetic Lethality Redefined Precision Oncology : Nature | May 2026

Introduction

The discovery of synthetic lethality between BRCA1/BRCA2 deficiency and PARP inhibition fundamentally transformed cancer therapeutics and became one of the defining advances in modern precision oncology. By selectively targeting DNA repair vulnerabilities in tumor cells, PARP inhibitors established a new paradigm in which inherited or acquired genomic defects could guide highly personalized cancer treatment.

Problem Statement

Before the development of PARP inhibitors, targeted cancer therapies largely focused on directly inhibiting activated oncogenic drivers. However, many tumor suppressor gene alterations, including BRCA1 and BRCA2 loss, were considered therapeutically “undruggable.” A major challenge was determining whether vulnerabilities created by defective DNA repair pathways could be exploited therapeutically without excessive toxicity to normal tissues.

Summary

This perspective reviews the scientific and clinical evolution of PARP inhibitor synthetic lethality over the past two decades and highlights its transformative impact on oncology. The original observation that PARP inhibition selectively kills BRCA-deficient cells established the first successful therapeutic strategy directly linked to a germline biomarker and fundamentally changed treatment approaches in breast, ovarian, prostate and pancreatic cancers. Beyond improving survival, PARP inhibitors also demonstrated that targeting DNA repair dependency could achieve meaningful efficacy with comparatively favorable tolerability. Importantly, the clinical success of PARP inhibitors extended the role of BRCA testing from hereditary cancer risk assessment to routine therapeutic decision-making, embedding germline genetics into mainstream oncology practice. The article also emphasizes the broader biologic significance of synthetic lethality, showing how functional redundancies within tumor cells create exploitable therapeutic dependencies. This concept has since driven extensive efforts to identify additional synthetic lethal interactions across cancer biology. At the same time, the review acknowledges ongoing challenges, including resistance mechanisms, incomplete biomarker precision and variability in response beyond canonical BRCA-mutated tumors. Overall, the PARP inhibitor story represents a landmark example of translational medicine in which fundamental biologic discovery directly reshaped cancer care and established synthetic lethality as a central framework for future targeted therapy development.